Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
9.260
+0.140 (+1.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
May 19, 2023
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.
Via
Benzinga
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120'
May 16, 2023
Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again.
Via
Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
May 05, 2023
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business...
Via
Benzinga
Mind Medicine: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Earnings Outlook For Mind Medicine
May 03, 2023
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
3 High-Growth Penny Stocks to Consider Buying in April 2023
May 01, 2023
Here are three high-growth penny stocks long-term investors may want to keep on their watch list, or buy, in April.
Via
InvestorPlace
April Psychedelic Drug Stocks Recap: The Ups And Downs
April 30, 2023
Via
Talk Markets
MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management
April 26, 2023
In this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ: MNMD), Robert Barrow.
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
April 20, 2023
Via
Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
April 17, 2023
Via
Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Via
Benzinga
80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial
April 17, 2023
Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive...
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
April 14, 2023
Via
Benzinga
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 14, 2023
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.
Via
Benzinga
Why Is Ocugen (OCGN) Stock Moving Today?
April 14, 2023
Ocugen (OCGN) stock is on the move Friday after the company revealed preliminary results from an ongoing clinical trial.
Via
InvestorPlace
US Stocks Mixed; Retail Sales Drop 1% In March
April 14, 2023
U.S. stocks traded mixed this morning, following the release of economic reports. Following the market opening Friday, the Dow traded up 0.08% to 34,055.40 while the NASDAQ fell 0.10% to 12,153.84. The...
Via
Benzinga
Why Is Mind Medicine (MNMD) Stock Up 26% Today?
April 14, 2023
Mind Medicine (MNMD) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial of lysergide (LSD).
Via
InvestorPlace
MindMed Reveals Topline Data From Mid-Stage Depression Study Evaluating Lysergide
April 14, 2023
Mind Medicine Inc's (NASDAQ: MNMD) collaborators have released topline data from a double-blind, investigator-initiated trial evaluating lysergide major depressive disorder (MDD).
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
Via
Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
April 13, 2023
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
April 12, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
April 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
April 10, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.